| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 02/19/2004 | WO2004014903A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 02/19/2004 | WO2004014894A1 Novel prodrugs of 1-methyl-2(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(n-2-pyridil-n-2-hydroxycarbonylethyl)-amide, production and use thereof as medicaments |
| 02/19/2004 | WO2004014859A2 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | WO2004014844A2 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 02/19/2004 | WO2004014430A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | WO2004014414A1 Novel uses of rfrp and ot7t022 |
| 02/19/2004 | WO2004014372A1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| 02/19/2004 | WO2004014369A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | WO2004014355A1 A peritoneal dialysis solution comprising a pyruvate |
| 02/19/2004 | WO2004014352A2 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | WO2004014304A2 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | WO2004007481A3 Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
| 02/19/2004 | WO2004007478A3 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 02/19/2004 | WO2003097852A3 Assay for identifying inhibitors of fc gamma riii signaling |
| 02/19/2004 | WO2003087318A3 Truncated 24 kda basic fibroblast growth factor |
| 02/19/2004 | WO2003065987A3 Granzyme b inhibitors |
| 02/19/2004 | WO2003065046A3 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 02/19/2004 | WO2003052051A3 Adeno-associated virus (aav) serotype 8 sequences |
| 02/19/2004 | WO2003045398A8 Methods of making and pharmaceutical formulations comprising 7alpha, 11beta-dimethy-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof |
| 02/19/2004 | WO2003037168A3 Methods and formulations for minimizing spasticity in blood vessel grafts |
| 02/19/2004 | WO2003027234A9 Small organic molecule regulators of cell proliferation |
| 02/19/2004 | WO2002070023A3 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation |
| 02/19/2004 | WO2002066498A3 Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity |
| 02/19/2004 | WO2002064160A3 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | WO2002024214A3 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 02/19/2004 | US20040034231 Amidinophenyl-4-aminoacetic acid derivative is useful for treating diseases such as thrombosis, apoplexy, cardiac infarction, inflammation and arteriosclerosis, which are associated with coagulation factors xa, IXa and thrombin |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034090 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/19/2004 | US20040034076 Such as methyl-3-azido-2-((4,6-dimethoxy-2-pyrimidinyl)oxy) 3,3-diphenylpropionate; for treatment of high blood pressure |
| 02/19/2004 | US20040034073 Analgesic agents, modulating the activity of a cannabinoid receptor, treating hypertension, inflammation, pain, autoimmune diseases, allergic diseases, glaucoma, multiple sclerosis, Huntington's chorea, spinal chord injury |
| 02/19/2004 | US20040034072 Aza-amino acid derivatives (factor Xa inhibitors 15) |
| 02/19/2004 | US20040034061 An antagonist of corticotropin releasing factor receptor, treating depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disorders, drug dependence |
| 02/19/2004 | US20040034027 E.g.N-(carbamimidoylphenyl)-N'-((1-(4-nitrophenyl)ethyl-2-phenyl -malonamide formate; reversible enzyme inhibitors of blood factor VIIa; a strong antithrombotic to treat thrombo-embolic diseases and restenoses; cardiovascular disorders |
| 02/19/2004 | US20040034012 Superior arginine vasopressin receptor antagonism; a 6-membered aromatic ring having nitrogen at the 2-position there of is substituted at 2 position of the imidazobenzazepine ring |
| 02/19/2004 | US20040034006 Combining blood product with (a porphyrin compound) a photosensitiser, and activating the photosensitiser |
| 02/19/2004 | US20040033995 Nitrogen compounds, stereoisomers and/or racemic mixtures used as enzyme inhibitors for prophylaxis of inflammatory diseases |
| 02/19/2004 | US20040033994 Use of compounds comprising a nitrogen-oxygen heterocycle |
| 02/19/2004 | US20040033993 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033992 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033991 Treating of cardiovascular and related pathologies |
| 02/19/2004 | US20040033990 Administering mixtures of heterocyclic imines, calcium channel blockers, adrenergic blocking agents, anticoagulants, diuretics and angiotensin converting enzyme inhibitors, for prophylaxis of heart diseases such as arrhythmias or necrosis |
| 02/19/2004 | US20040033989 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033946 Cell damage inhibitor |
| 02/19/2004 | US20040033945 Pharmaceutical compositions for treating asthenia or anaemia or for making a food supplement |
| 02/19/2004 | US20040033936 Reduced or "leuco" forms produced and/or stabilised by mixing the unreduced compounds or the reduced compounds, respectively, with acid and a sulphydryl compound, especially a sulphur-containing amino acid, or peptide or derivative |
| 02/19/2004 | US20040033258 Compression molded blend of a basic medicinal component having an unpleasant taste, a saccharide, a polyanionic polymer, a corrigent, and carboxymethylcellulose; quickly disintegrating in the oral cavity. |
| 02/19/2004 | US20040033222 Anticoagulant and fibrinolytic therapy uning p38 MAP kinase inhibitors |
| 02/19/2004 | US20040033200 Modified FVII in treatment of ARDS |
| 02/19/2004 | DE10235639A1 New prodrugs of benzimidazole-5-carboxamide derivative thrombin inhibitor, useful for treating or preventing thrombotic diseases, are well tolerated on subcutaneous injection |
| 02/19/2004 | CA2495518A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2494865A1 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | CA2494298A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | CA2493660A1 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | CA2493297A1 Methods to reprogram splice site selection in pre-messenger rnas |
| 02/19/2004 | CA2493008A1 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 02/18/2004 | EP1389236A2 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof |
| 02/18/2004 | EP1389206A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 02/18/2004 | EP1389205A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
| 02/18/2004 | EP1389137A2 Compositions for protein delivery via the pulmonary route |
| 02/18/2004 | EP1389112A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
| 02/18/2004 | EP1389103A2 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents |
| 02/18/2004 | EP1216248B1 Triazolopyrimidine derivatives |
| 02/18/2004 | EP1216238B1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 02/18/2004 | EP1192156B1 Bispidine compounds useful in the treatment of cardiac arrhythmias |
| 02/18/2004 | EP1123314B1 Use of a cytokine-producing lactococcus strain to treat colitis |
| 02/18/2004 | EP0956860B1 Hematopoietic function restorative agent |
| 02/18/2004 | EP0948337B1 Treatment of hemoglobin containing erythrocytes with nitric oxide |
| 02/18/2004 | EP0944631B1 Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
| 02/18/2004 | CN1476448A Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 02/18/2004 | CN1476447A Aminothiazoles and their use as adenosine receptor antagonists |
| 02/18/2004 | CN1476446A Benzodiazepine derivative |
| 02/18/2004 | CN1476433A Substituted benzene derivatives or salts thereof |
| 02/18/2004 | CN1476424A 萘衍生物 Naphthalene Derivatives |
| 02/18/2004 | CN1475486A Chiral 3-aryl benzo phthalein kind compound, synthesis method and use |
| 02/18/2004 | CN1475251A Chinese medicinal herb preparation for treating ascites type liver cancer |
| 02/18/2004 | CN1475226A Application of nano copper powder in preparation of antisenility medicine |
| 02/18/2004 | CN1138760C Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 02/18/2004 | CN1138550C Process of producing extracts of shark |
| 02/18/2004 | CN1138546C Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine |
| 02/18/2004 | CN1138505C Anti-angiogenic compositions and method of use |
| 02/18/2004 | CN1138472C Dipeptide apoptosis inhibitors and use thereof |
| 02/17/2004 | US6693132 Methods for using alkanoyloxymethyl esters |
| 02/17/2004 | US6693121 As inhibitors of serine proteases of the coagulation cascade and compounds, used for anticoagulant therapy forprophylaxis of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases |
| 02/17/2004 | US6693120 Spray drying of thrombin inhibitors |
| 02/17/2004 | US6693118 E.G., 1-(2-(6,7-METHYLENEDIOXYNAPHTH-2-YL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE AND 1-2-(4-CYCLOHEXENYLPHENYL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6 -TETRAHYDROPYRIDINE; apoptosis inhibition; treatment of graft rejection or of acute or chronic rheumatoid arthritis |
| 02/17/2004 | US6693115 2-acetoxy-5-(alpha-cyclopropylcarbonyl-o-fluorobenzyl)--4,5,6,7 -tetrahydrothieno(3,2-c)-pyridine, particularly the hydrochloride and the maleate |
| 02/17/2004 | US6693113 As immunomodulators and for inducing cytokine biosynthesis in animals, for therapy of viral infections |
| 02/17/2004 | US6693109 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| 02/17/2004 | US6693108 Pyrimidinyl-guanidine derivatives |
| 02/17/2004 | US6693102 Pyridine-substituted pyrazolopyridine derivatives |
| 02/17/2004 | US6693101 Alkanoic acid derivative; integrin receptor antagonist |
| 02/17/2004 | US6693098 Carboxylic acid or tetrazole derivatives containing carbamate groups are useful for treating the conditions associated with the urinary tract, pain, inflammation, respiratory states, edema formation of hypotensive vascular diseases |
| 02/17/2004 | US6693096 Treatment of inflammation-associated disorders using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
| 02/17/2004 | US6693075 Factor viia polypeptide comprising modified carboxyglutamic acid domain; enhancing membrane binding affinity and activity |
| 02/17/2004 | US6692943 Persephin and related growth factors |
| 02/17/2004 | US6692935 Fusion of peptide or protein association domains designed to assemble in a complementary fashion, thereby providing multifunctional (poly)peptides |
| 02/17/2004 | US6692772 Administered between 15 and 90 minutes prior to exposure of the subject to thrombogenic stimuli |